EC grants conditional marketing authorization for Pfizer’s Bosulif
Bosulif is authorized in Europe for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) who